PLC Systems, a provider of medical device technologies, has secured a new method patent entitled 'Patient Hydration Method' from the US Patent and Trademark Office for its RenalGuard therapy and the RenalGuard device.
The patent, which covers the use of RenalGuard therapy and the RenalGuard device to protect patients' kidneys from potentially toxic therapeutic agents such as those used in cancer treatments, significantly widens the company's intellectual property position.
The use of the RenalGuard technology reduces the risk of acute kidney injury (AKI) from exposure to contrast agents that lead to contrast-induced AKI (CI-AKI).
Designed to quickly remove contrast dyes that are harmful to patients with impaired kidney function, RenalGuard technology can prevent the occurrence of CI-AKI in millions of at-risk patients.
This technology helps in maintaining a high urine output that in turn allows the body to quickly eliminate the contrast agent and reduce its toxic effects.
CI-AKI can cause death or may require the patient to undergo a kidney transplant, and treament of this condition can be very expensive.
PLC Medical Systems director of marketing and engineering Andrew Halpert said; "Receiving this method patent in the US for our proprietary RenalGuard Therapy is noteworthy in our efforts to protect our technology and the millions of patients from the adverse effects of contrast dyes, chemotherapy and other toxic agents."
"Combined with the positive results produced in the investigator-sponsored clinical trials of RenalGuard in Europe, we believe this additional patent will be a useful tool in our efforts to accelerate and expand the use of RenalGuard around the world," added Halpert.